143 related articles for article (PubMed ID: 34262681)
21. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
22. IgG4-related disease: association between chronic rhino-sinusitis and systemic symptoms.
Gao Y; Zheng M; Cui L; Chen N; Wang YN; Zhan YT; Wang ZG
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2013-2019. PubMed ID: 29948263
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis.
Sun Y; Ma L; Ma L; Kong X; Chen H; Lv P; Lin J; Liu H; Yan Y; Ji Z; Yang C; Dai S; Wan W; Zou Y; Jin X; Jiang L
Rheumatol Int; 2017 Dec; 37(12):2019-2026. PubMed ID: 29030659
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
25. Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy.
Wang M; Zhang P; Lin W; Fei Y; Chen H; Li J; Zhang L; Zheng W; Li Y; Zeng X; Zhou J; Lai Y; Liu X; Xue H; Cui Y; Zhou L; Zhao J; Zhang W
Arthritis Res Ther; 2019 Feb; 21(1):44. PubMed ID: 30709411
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial.
Zhang P; Gong Y; Liu Z; Liu Y; Lin W; Li J; Wang M; Liu X; Fei Y; Chen H; Peng L; Li J; Zhou J; Shi Q; Zhang X; Shen M; Zeng X; Zhang F; Li Y; Zhao Y; Zhang W
Int J Rheum Dis; 2019 Aug; 22(8):1479-1488. PubMed ID: 31245907
[TBL] [Abstract][Full Text] [Related]
27. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients.
Wallace ZS; Deshpande V; Mattoo H; Mahajan VS; Kulikova M; Pillai S; Stone JH
Arthritis Rheumatol; 2015 Sep; 67(9):2466-75. PubMed ID: 25988916
[TBL] [Abstract][Full Text] [Related]
28.
Zongfei J; Rongyi C; Xiaomeng C; Lili M; Lingying M; Xiufang K; Xiaomin D; Zhuojun Z; Huiyong C; Ying S; Lindi J
Front Immunol; 2020; 11():1272. PubMed ID: 32733444
[No Abstract] [Full Text] [Related]
29. Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.
Zongfei J; Lingying M; Lijuan Z; Ying S; Rongyi C; Dongmei L; Xiufang K; Xiaomin D; Lili M; Huiyong C; Lindi J
Clin Rheumatol; 2021 Jun; 40(6):2293-2300. PubMed ID: 33151477
[TBL] [Abstract][Full Text] [Related]
30. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial.
Wu Q; Chang J; Chen H; Chen Y; Yang H; Fei Y; Zhang P; Zeng X; Zhang F; Zhang W
Int J Rheum Dis; 2017 May; 20(5):639-646. PubMed ID: 28556584
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.
Zhang X; Zhang P; Peng L; Fei Y; Zhang W; Feng R; Zhang W
Clin Rheumatol; 2018 Dec; 37(12):3387-3395. PubMed ID: 29948354
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort.
Gan L; Luo X; Fei Y; Peng L; Zhou J; Li J; Lu H; Liu Z; Zhang P; Liu X; Zhang W
Front Med (Lausanne); 2021; 8():784520. PubMed ID: 34977087
[No Abstract] [Full Text] [Related]
34. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
[TBL] [Abstract][Full Text] [Related]
35. Increased Circulating Th1 and Tfh1 Cell Numbers Are Associated with Disease Activity in Glucocorticoid-Treated Patients with IgG4-Related Disease.
Xia C; Liu C; Liu Y; Long Y; Xu L; Liu C
J Immunol Res; 2020; 2020():3757015. PubMed ID: 33313326
[TBL] [Abstract][Full Text] [Related]
36. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
Li X; Li H; Chen J; He Q; Lv R; Lin W; Li Q; He X; Qu L; Suya W
Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
[TBL] [Abstract][Full Text] [Related]
37. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Omar D; Chen Y; Cong Y; Dong L
Rheumatology (Oxford); 2020 Apr; 59(4):718-726. PubMed ID: 31511884
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
[TBL] [Abstract][Full Text] [Related]
39. IgG4-related disease in a Chinese cohort: a prospective study.
Chen H; Lin W; Wang Q; Wu Q; Wang L; Fei Y; Zheng W; Fei G; Li P; Li YZ; Zhang W; Zhao Y; Zeng X; Zhang F
Scand J Rheumatol; 2014; 43(1):70-4. PubMed ID: 24134471
[TBL] [Abstract][Full Text] [Related]
40. IgG4-related fibrosing mediastinitis: clinical presentation, treatment efficacy and comparison with IgG4-RD without fibrosing mediastinitis.
Zhang P; Han X; Li J; Liu Z; Lu H; Luo X; Liu C; Peng L; Fei Y; Zeng X; Zhang W; Zeng X
Clin Exp Rheumatol; 2020; 38(6):1206-1214. PubMed ID: 32896252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
